Facial filler and neurotoxin complications.
Botulinum neuromodulators and injectable dermal fillers have become part of the armamentarium in the treatment of facial aging. Their successful use requires a fundamental knowledge of anatomy and physiology and a sound understanding of their risks and complications. Although neuromodulators and fillers continue to demonstrate a strong record of safety, several notable risks exist.
Maas Clinic for Aesthetic and Facial Plastic Surgery, University of California-San Francisco, CA, USA. Drnettar@maasclinic.com
Kartik
K
Nettar
Corey
C
Maas
D000328:Adult; D000369:Aged, 80 and over; D001672:Biocompatible Materials / Q000009:adverse effects*; D001763:Blepharoptosis / Q000209:etiology; D019274:Botulinum Toxins, Type A / Q000009:adverse effects*; D003288:Contusions / Q000209:etiology; D003357:Cosmetic Techniques / Q000009:adverse effects*; D005138:Eyebrows / Q000473:pathology; D005145:Face / Q000601:surgery*; D005148:Facial Dermatoses / Q000139:chemically induced; D005260:Female; D005546:Forehead / Q000473:pathology; D006560:Herpes Labialis / Q000209:etiology; D006801:Humans; D006820:Hyaluronic Acid / Q000009:adverse effects; D007271:Injections, Intradermal / Q000009:adverse effects; D007279:Injections, Subcutaneous / Q000009:adverse effects; D008875:Middle Aged; D009336:Necrosis; D009465:Neuromuscular Agents / Q000009:adverse effects*; D009498:Neurotoxins / Q000009:adverse effects*; D010859:Pigmentation Disorders / Q000139:chemically induced; D012060:Rejuvenation; D018570:Risk Assessment; D012449:Safety; D015595:Skin Aging / Q000473:pathology; D055682:Viscoelastic Substances / Q000009:adverse effects
D001672:Biocompatible Materials; D009465:Neuromuscular Agents; D009498:Neurotoxins; D055682:Viscoelastic Substances; D006820:Hyaluronic Acid; D019274:Botulinum Toxins, Type A